Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has started an underwritten public offering and private placement of shares of its common stock and pre-funded warrants. The offering is not contingent on a private placement to Balyasny Asset Management. The proposed offerings are subject to market conditions and no assurance is given on completion. Leerink Partners, Cantor, Stifel, and Oppenheimer & Co. are managing the public offering. The offering is being made under a Registration Statement on Form S-3. Shares in the concurrent private placement have not been registered. This press release is not an offer to sell securities. Lexeo is a genetic medicine company focused on cardiovascular diseases.

Read more at GlobeNewswire: Lexeo Therapeutics Announces Proposed Offering of Common